US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ヨーロッパ
EU
Stradim Espace Finances SA (ALSAS) 銘柄情報

Stradim Espace Finances SA (ALSAS)

4.54

0.00

(0.00%)

終了 7月5日 12:30AM

Stradim Espace Finances SA (ALSAS) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

4.54

( - )

買値

4.52

売値

4.54

出来高

0.00

0.00 日の範囲 0.00

4.04 52 週間の範囲 6.50

時価総額

前日終値

4.54

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

1,053 €

発行済株式数

3,439,760

配当利回り

(2.20%)

PER

9.18

1 株当たり利益 (EPS)

0.49

歳入

112.99M

純利益

1.7M

Stradim Espace Finances SA develops real estate properties in France. It designs, builds, and markets new homes and apartments; operates and leases business premises and offices; and buys land. The company was incorporated in 1990 and is headquartered in Entzheim, France. Stradim Espace Finances SA ... Stradim Espace Finances SA develops real estate properties in France. It designs, builds, and markets new homes and apartments; operates and leases business premises and offices; and buys land. The company was incorporated in 1990 and is headquartered in Entzheim, France. Stradim Espace Finances SA operates as a subsidiary of AST Groupe. 詳細を表示

セクター

Real Estate

業界

Real Estate

ウェブサイト

www.stradim.fr

本社

Entzheim, France

設立

1990

Stradim Espace Finances SA is listed in the Real Estate sector of the ユーロネクスト with ticker ALSAS. The last closing price for Stradim Espace Finances was 4.54 €. Over the last year, Stradim Espace Finances shares have traded in a share price range of 4.04 € to 6.50 €.

Stradim Espace Finances currently has 3,439,760 shares in issue. The market capitalisation of Stradim Espace Finances is 15.62 € million. Stradim Espace Finances has a price to earnings ratio (PE ratio) of 9.18.

Calendrier des sociétés sur 15 jours

15/06/2015 Euromedis Groupe (EU - EMG) Chiffre d'affaires 3ème trimestre Les Hotels Baverez (EU - ALHRP) Assemblée générale...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.06	-1.30434782609	4.6	4.6	4.54	214	4.59496112	DE
4	0.16	3.65296803653	4.38	4.6	4.1	974	4.4991418	DE
12	0.34	8.09523809524	4.2	5.15	4.04	649	4.40975747	DE
26	0.22	5.09259259259	4.32	5.15	4.04	390	4.41712103	DE
52	-1.91	-29.6124031008	6.45	6.5	4.04	468	5.15168978	DE
156	-2.21	-32.7407407407	6.75	8.4	4.04	512	6.14512179	DE
260	-3.26	-41.7948717949	7.8	8.4	4.04	575	6.67165429	DE

ALSAS - Frequently Asked Questions (FAQ)

What is the current Stradim Espace Finances SA share price?

The current share price of Stradim Espace Finances SA is 4.54 €

How many Stradim Espace Finances SA shares are in issue?

Stradim Espace Finances SA has 3,439,760 shares in issue

What is the market cap of Stradim Espace Finances SA?

The market capitalisation of Stradim Espace Finances SA is EUR 15.62M

What is the 1 year trading range for Stradim Espace Finances SA share price?

Stradim Espace Finances SA has traded in the range of 4.04 € to 6.50 € during the past year

What is the PE ratio of Stradim Espace Finances SA?

The price to earnings ratio of Stradim Espace Finances SA is 9.18

What is the cash to sales ratio of Stradim Espace Finances SA?

The cash to sales ratio of Stradim Espace Finances SA is 0.14

What is the registered address of Stradim Espace Finances SA?

The registered address for Stradim Espace Finances SA is Aéroparc de Strasbourg, Entzheim, Alsace, 67960

What is the Stradim Espace Finances SA website address?

The website address for Stradim Espace Finances SA is www.stradim.fr

Which industry sector does Stradim Espace Finances SA operate in?

Stradim Espace Finances SA operates in the Real Estate sector

SonicProphet49

SonicProphet49 6分前

Cryptocurrency Recovery Services: Why Acting Fast Can Make a Difference

Recovering Lost or Stolen Cryptocurrency: The Importance of Time

The cryptocurrency market continues to grow, bringing new opportunities for investors, traders, and businesses worldwide. Unfortunate

Philbot

Philbot 9分前

Valid points. Won't it get delisted by not paying its annual listing dues or annual filing statements? It probably should have been auto-delisted by now.

GoodGuyBill

GoodGuyBill 14分前

Thanks. Wish I could return the complement.

https://investorshub.advfn.com/uimage/uploads/2026/7/4/rlzkdBadpost.jpg

m0n

Imagine having a product since 2009 LoL.
Cant even pay the bills and continue to have decades upon decadesof $2.2 million in deficits. LOL
No One is Fooled

m0n

How many shareholders have passed away? I m aware of one but feel there’s more.
I FU S website has ionic studies from 2009. LoL
30 YEARS IS FASTLY APPROACHING! LoL
Same o Same o, Keep the awareness on the possibilities LoL.
No One is Fooled

barnyarddog

barnyarddog 26分前

AI Overview - Avalanche Treasury Co. (ticker: AVAT) is a Nasdaq-listed operating company that provides public market investors with direct exposure to the Avalanche blockchain ecosystem.

Rather than merely stockpiling digital assets, AVAT actively allocates capital across the Avalanc

m0n

Past 6 months WIP $150 &$130k LoL
Can’t even pay the bills without door knocking for SSI $$$ in January 2026LoL
What a Joke!
No One is Fooled

TightCoil

TightCoil 36分前

Glen Bradford - Looks Like Trump Team Simply Maximizing Frannie IPO (OTCMKTS:FNMAS)
Seeking Alpha - 17 hours ago

TechBullion
Could Pepeto Be the Best Crypto Presale to Buy as
Fannie Mae Opens the Door to Crypto Mortgages?
5 hours ago

weenphan

weenphan 43分前

https://www.otcmarkets.com/stock/CVALF/profile

Kool Aid Man

Kool Aid Man 44分前

Measly $44k left in the gas tank

40 million shares left to issue x .0011

No one goes public if they intend to self finance operations. The whole point is to print and sell shares to raise money...not to reward old bag holders who were conned by Miro years ago. Why split

jondoeuk

jondoeuk 45分前

Calling this the "gold standard" doesn't answer all the underlying concerns. This isn't a refinement of the original external-control analysis either. It uses a completely different set of external comparator trials. That means the reported survival estimate depends on which external patients are se

manibiotech

manibiotech 47分前

Yes we all know that . The previous external control arm patients were “external” , and the one’s in new PSM analysis are also different ‘external’ patients with patient level propensity matching ( so even better controls) and show even better treatment benefit . So again, what is the point you are

Naught

Naught 48分前

Should we expect some notices from. PAC in the very near term then...?

weenphan

weenphan 48分前

I posted on the PCHM board for over a decade. I bought PCHM as low as .0013 and sold stock as high as $5 plus. It was a once in a lifetime percentage gainer. My aliases were LMLYP, Rosesarefree and GeneandDean, which all are references to a band Ween. I'm weenphan on this board.

newflow

newflow 48分前

Ron, Dissolved vs Extinct
No Altaba distributed immediately before dissolution, can you find any company distributing value to equity holders after its complete dissolution long-form or regular Dissolution.
Gemini's Response:
It is important to clarify a key point about Delaware

DA88

Can someone explain who this guy is and why his perspective matters? Love that he is positive, but he doesn’t look like he is anything more than a shareholder.

PickStocks

PickStocks 52分前

Yes….but we do not have anything to do with Paladin. So it means nothing which is easily verified by a simple phone call….

jondoeuk

jondoeuk 56分前

Whether this particular analysis has been submitted is something nobody outside NWBO and the MHRA knows.

jondoeuk

jondoeuk 58分前

This is not simply a refinement of the published JAMA Oncology analysis. It's a different external-control analysis built from a different pool of comparator trials. The fact they constructed a propensity-score matched analysis using individual patient data from AVAGLIO, CENTRIC, and CORE, means the

ihorchu

ihorchu 60分前

A fantastic day to remember! Since no humidity here, heat is very tolerable.

jondoeuk

jondoeuk 1時間前

'While encouraging, our clinical findings must be interpreted with caution. Even though this was a randomized clinical trial (randomization software assigned patients to TLR agonist/placebo groups), the small number of patients enrolled contributed to an imbalance in patient selection between the tr

kevindenver

kevindenver 1時間前

Nowhere in the interview was "Blarcamesine" mentioned. There was a snippet towards the end where autophagy is mentioned.

Maybe you hallucinated that this interview was related to blarcamesine?

A transcript of the interview can be found here:
https://podcasts.hap

TightCoil

TightCoil 1時間前

Yes, next week is the week we FLY

Stradim Espace Finances

Skylight Health

BetaShares Capital

Ci Munro Alternative Glo...

Halmont Properties

Sun Life Mfs Global Tota...

Euronext Developed Asia ...

First Trust abrdn Global...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。